Compare 10X Genomics Inc (TXG) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs UnitedHealth Group Inc — how do they compare? 10X Genomics Inc trades at $80.87 (market cap $10.07B), while UnitedHealth Group Inc trades at $379.5 (market cap $332.96B). The key difference: UnitedHealth Group Inc is far larger — about 33.1× 10X Genomics Inc's market cap, and UnitedHealth Group Inc pays a 2.5% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and UnitedHealth Group Inc for 97 Days on average.
| TXG | UNH | |
|---|---|---|
Market Cap | $10.07B | $332.96B |
Volume | 5,657,286 | 7,273,749 |
Sector | Health | Health |
52-Week High | $97.74 | $436.35 |
52-Week Low | $11.48 | $259.02 |
Typical Hold Time | 91 Days | 97 Days |
Enterprise Value | $9.59B | $374.82B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
UnitedHealth Group (UNH) trades at $375.98, showing minor daily weakness but maintaining a bullish technical signal. The company reported strong Q2 2026 earnings, beating estimates, and reaffirmed its full-year outlook. Revenue growth remains robust, though net margins have compressed from prior years. Analyst sentiment is overwhelmingly positive, with a consensus price target of $473.89 implying significant upside.
The outlook for UNH is favorable, driven by earnings momentum and strategic initiatives like AI investment. Key risks include regulatory pressures and medical cost trends. The stock presents a compelling opportunity for investors seeking exposure to a leading healthcare company with solid fundamentals and Wall Street support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
